PF-04523655
DrugThis is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
Other names: REDD14NP
NCT Number: NCT00725686
The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD
Looking for future studies?
Notify Me50 year and older
All sexes
Interventional
Phase 1
Pfizer Investigational Site, Tel Aviv, Israel
Dose escalation safety study
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
Other names: REDD14NP
Time frame: Over a 24-Month Period
Time frame: Day 14
Time frame: Day 14
Time frame: Monthly
Time frame: Day 14
Quark Pharmaceuticals
Industry
A Phase I Open-Label, Dose Escalation Trial Of REDD14NP Delivered By A Single Intravitreal Injection To Patients With Choroidal Neovascularization (CNV) Secondary To Exudative Age-Related Macular Degeneration ("Wet AMD").
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04679935
Age-Related Macular Degeneration, Choroid Diseases
Regensburg, Bavaria, Germany
View Trial DetailsNCT04005352
Age-Related Macular Degeneration, Choroid Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT05662943
Age-Related Macular Degeneration, Choroid Diseases
Seoul, South Korea
View Trial DetailsNCT03024424
Age-Related Macular Degeneration, Choroid Diseases
Salt Lake City, Utah, United States
View Trial Details